
NYSEARCA:XLV
This summary was created by AI, based on 3 opinions in the last 12 months.
The Health Care Select Sector SPDR Fund (XLV) has garnered positive reviews from multiple experts, showcasing its ability to outperform the S&P 500 index significantly, with a notable 12% excess return over the past three months and a year-to-date return of 26.8%. It is perceived as a safe and steady investment choice, highlighted by its low beta of 0.51, which implies lower volatility compared to the broader market. The current market trend indicates a shift away from AI sectors, giving healthcare stocks a prime opportunity for growth. Experts suggest that there is potential for short-term alpha in the healthcare sector, influenced by ongoing developments in health treatments, such as GLP-1 medications. While predictions for 2026 suggest continued growth, the current year's substantial increase makes XLV an attractive prospect for investors seeking stability amidst market fluctuations.
This tends to be late stage and has been growing rapidly in the last 3-to-4 months. It is just starting to break out. Within the underlying sector, more industries are starting to do well pharma, services, distributors and hospitals are all improving and the US-based policy risk seems to be toning down. (Analysts’ price target was not provided)
Better to buy the holdings? He doesn't buy ETFs, because he's an active manager. He'd rather buy the individual stocks, and he doesn't know what's in this ETF, though Thermo-Fisher, a key holding, is a fine company. In this sector, he owns Anthem, Abbvie and CVS, for example. Healthcare isn't in the sun now, but you can do well if you pick the right stocks.